High‐Affinity Peptide‐Drug Conjugate Ligands for the TRIM24 PHD and Bromodomain
Chemistry – A European Journal · 2025
DOI: 10.1002/chem.202503011 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry – A European Journal, 2025. Verfasst von Michael A Platt und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, University of Oxford, Chemistry Research Laboratory, Mansfield Road, Oxford, OX1 3TA, U.K. Hauptthemen laut MEDLINE: Peptides, Carrier Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biotechnology and Biological Sciences Research Council.
Abstract (Originalsprache)
TRIM24 is an epigenetic transcriptional coregulator that “reads” KMe 3 and KAc histone modifications via its tandem plant homeodomain (PHD) and bromodomain (BRD), respectively. The PHD and BRD are potential therapeutic targets due to the roles of TRIM24 in breast cancer progression. However, there are currently no small‐molecule ligands for the PHD, and existing TRIM24 BRD inhibitors lack selectivity over the main off‐target, BRPF1. Here, we report the development of the first bivalent tool molecules capable of simultaneously engaging both the TRIM24 PHD and BRD. Key to this strategy was the identification of effective KMe 3 bioisosteres that enhance H3 peptide binding to the TRIM24 PHD. The most promising of these was incorporated into a nine amino acid H3‐mimicking peptide, and linked to a TRIM24 BRD ligand. The resulting peptide‐drug conjugates (PDCs) bind to TRIM24 with picomolar affinity and a slow dissociation rate ( k off ), which is driven by an in cis bivalent binding mode. Although the PDCs showed limited effects on breast cancer cell proliferation in vitro, this work underscores their potential as tools for studying previously unliganded reader domains and consequently advancing our understanding of multivalent epigenetic regulation in disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, University of Oxford, Chemistry Research Laboratory, Mansfield Road, Oxford, OX1 3TA, U.K.
- Centre for Medicines Discovery, University of Oxford, Nuffield Department of Medicine Research Building, Roosevelt Drive, Oxford, OX3 7FZ, U.K.
- Department of Oncology, University of Oxford, Nuffield Department of Medicine Research Building, Roosevelt Drive, Oxford, OX3 7FZ, U.K.
- Department of Chemistry & Biochemistry, University of California, Los Angeles, 607 Charles E. Young Drive East, Los Angeles, California, 90095, U.S.A.
ORCID-Profile: Michael A Platt, Liwen Song, Stuart J Conway
Förderung
- Biotechnology and Biological Sciences Research Council
Zitieren
APA
Platt, M. A., Kot, E., Martin, L. A. W., Wallabrègue, A. L. D., Song, L., Boyd, A. M., Koekemoer, L., Hammond, E. M., & Conway, S. J. (2025). High‐Affinity Peptide‐Drug Conjugate Ligands for the TRIM24 PHD and Bromodomain. Chemistry – A European Journal. https://doi.org/10.1002/chem.202503011
Vancouver
Platt MA, Kot E, Martin LAW, Wallabrègue ALD, Song L, Boyd AM, et al. High‐Affinity Peptide‐Drug Conjugate Ligands for the TRIM24 PHD and Bromodomain. Chemistry – A European Journal. 2025. doi:10.1002/chem.202503011
BibTeX
@article{Platt2025,
author = {Platt, Michael A and Kot, Ekaterina and Martin, Louise A W and Wallabrègue, Antoine L D and Song, Liwen and Boyd, Alistair M and Koekemoer, Lizbé and Hammond, Ester M and Conway, Stuart J},
title = {High‐Affinity Peptide‐Drug Conjugate Ligands for the TRIM24 PHD and Bromodomain},
journal = {Chemistry – A European Journal},
year = {2025},
doi = {10.1002/chem.202503011}
}
EUVIMED